Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Sep;18(3):355–360. doi: 10.1111/j.1365-2125.1984.tb02476.x

The potentiation of acenocoumarol anticoagulant effect by amiodarone.

M Arboix, M E Frati, J R Laporte
PMCID: PMC1463659  PMID: 6487475

Abstract

Out of 690 patients (337 males and 353 females) on long-term acenocoumarol therapy, 80 (35 males and 45 females) were taking amiodarone. Forty patients had started amiodarone treatment while being treated with acenocoumarol. Of these, nine patients had begun amiodarone treatment while taking acenocoumarol. The relation between the daily dose of acenocoumarol and the prothrombin ratio (AC dose/PR ratio) has been considered a useful indicator to study the interaction between amiodarone and acenocoumarol. Differences of acenocoumarol daily dose between takers and non-takers of amiodarone were statistically significant (t = 5.35; P less than 0.001) for the whole population, for all the age groups, and also among males (t = 2.43; P less than 0.01) as well as among females (t = 5.38; P less than 0.001). Out of 40 patients chronically treated with acenocoumarol in whom amiodarone was instituted, 32 showed a decrease of the AC dose/PR ratio, while in eight patients no change was recorded (paired t-test, t = 5.82; P less than 0.001). In 15 patients who were being concomitantly treated with acenocoumarol and amiodarone, amiodarone was discontinued. An increase of the AC dose/PR ratio was recorded (paired t-test, t = 4.01; P less than 0.001). Nine patients had started treatment with amiodarone while receiving acenocoumarol and a decrease of the AC dose/PR ratio was documented; amiodarone was discontinued some months later, and an increase of the AC dose/PR ratio was seen.

Full text

PDF
355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Hamer A., Peter T., Mandel W. J., Scheinman M. M., Weiss D. The potentiation of warfarin anticoagulation by amiodarone. Circulation. 1982 May;65(5):1025–1029. doi: 10.1161/01.cir.65.5.1025. [DOI] [PubMed] [Google Scholar]
  2. Husted S., Andreasen F. The influence of age on the response to anticoagulants. Br J Clin Pharmacol. 1977 Oct;4(5):559–565. doi: 10.1111/j.1365-2125.1977.tb00786.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kannan R., Nademanee K., Hendrickson J. A., Rostami H. J., Singh B. N. Amiodarone kinetics after oral doses. Clin Pharmacol Ther. 1982 Apr;31(4):438–444. doi: 10.1038/clpt.1982.57. [DOI] [PubMed] [Google Scholar]
  4. Lalloz M. R., Byfield P. G., Greenwood R. M., Himsworth R. L. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J Pharm Pharmacol. 1984 Jun;36(6):366–372. doi: 10.1111/j.2042-7158.1984.tb04400.x. [DOI] [PubMed] [Google Scholar]
  5. Martinowitz U., Rabinovich J., Goldfarb D., Many A., Bank H. Interaction between warfarin sodium and amiodarone. N Engl J Med. 1981 Mar 12;304(11):671–672. doi: 10.1056/NEJM198103123041116. [DOI] [PubMed] [Google Scholar]
  6. Moysey J. O., Jaggarao N. S., Grundy E. N., Chamberlain D. A. Amiodarone increases plasma digoxin concentrations. Br Med J (Clin Res Ed) 1981 Jan 24;282(6260):272–272. doi: 10.1136/bmj.282.6260.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. O'Malley K., Stevenson I. H., Ward C. A., Wood A. J., Crooks J. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol. 1977 Jun;4(3):309–314. doi: 10.1111/j.1365-2125.1977.tb00718.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rees A., Dalal J. J., Reid P. G., Henderson A. H., Lewis M. J. Dangers of amiodarone and anticoagulant treatment. Br Med J (Clin Res Ed) 1981 May 30;282(6278):1756–1757. doi: 10.1136/bmj.282.6278.1756-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Routledge P. A., Chapman P. H., Davies D. M., Rawlins M. D. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol. 1979 Jun 12;15(5):319–322. doi: 10.1007/BF00558434. [DOI] [PubMed] [Google Scholar]
  10. Shepherd A. M., Hewick D. S., Moreland T. A., Stevenson I. H. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977 Jun;4(3):315–320. doi: 10.1111/j.1365-2125.1977.tb00719.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Stäubli M., Bircher J., Galeazzi R. L., Remund H., Studer H. Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol. 1983;24(4):485–494. doi: 10.1007/BF00609891. [DOI] [PubMed] [Google Scholar]
  12. van Kempen G. M., Koot-Gronsveld E. A., de Wolfe F. A. Quantitative and qualitative analysis of the anticoagulant acenocoumarol in human plasma. J Chromatogr. 1978 Mar 1;145(2):332–335. doi: 10.1016/s0378-4347(00)81359-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES